Knopp Biosciences to commence phase 2 clinical trial of dexpramipexole
Knopp Biosciences announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. March 20, 2019